Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07011706 · ClinicalTrials.gov registry record · Phase 2
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis and Eczema, sponsored by Aclaris Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
- 20
- Study locations
NCT07011706: Recruiting Phase 2 study of Atopic Dermatitis and Eczema, sponsored by Aclaris Therapeutics.
NCT07011706 is a Phase 2 study of Atopic Dermatitis and Eczema that is actively recruiting participants, run by Aclaris Therapeutics. The registered enrollment target is 96 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07011706, a Phase 2 study of Atopic Dermatitis and Eczema, is actively recruiting participants, sponsored by Aclaris Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
Primary Outcome
Percent change from baseline in EASI score at Week 24
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ATI-045
Study Locations (20)
California
- Aclaris Clinical Site - Beverly Hills
- Aclaris Study Site - Encinitas
- Aclaris Clinical Site - Encino
- Aclaris Clinical Site - Huntington Beach
- Aclaris Study Site - Los Angeles
- Aclaris Study Site - Oceanside
- Aclaris Study Site - Santa Monica
- Aclaris Clinical Site - Sherman Oaks
- Aclaris Clinical Site - Thousand Oaks
Florida
- Aclaris Study Site - Coral Gables
- Aclaris Clinical Site - Hollywood
- Aclaris Clinical Site - Jacksonville
- Aclaris Clinical Site - Margate
- Aclaris Study Site - North Miami Beach
- Aclaris Study Site - Sweetwater
- Aclaris Study Site - Tampa
- Aclaris Clinical Site - Wellington
Arizona
- Aclaris Clinical Site - Phoenix
- Aclaris Clinical Site - Tucson
Arkansas
- Aclaris Study Site - Bryant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2025-05-30 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
What NCT07011706 shows while recruiting
NCT07011706 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (84% lower).
The record links to 5 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07011706 names 20 study sites across 4 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT07011706 about?
NCT07011706 is a clinical study titled "ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis". This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
What is the current status of trial NCT07011706?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2025-05-30. Estimated completion is 2026-10.
What conditions does trial NCT07011706 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Eczema, Dermatitis, Atopic, AD.
What interventions are being tested in trial NCT07011706?
The interventions under investigation include: Placebo (DRUG), ATI-045 (DRUG).
Who is sponsoring clinical trial NCT07011706?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07011706 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07011706's enrollment target sits among peer trials
96 87th of 150 higher than 64 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI